Dossier assessment
Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations
Patients with L858R or Del19 mutations: Advantages in overall survival and individual side effects are offset by numerous disadvantages in several outcome categories. Other mutations: No data available. Added benefit not proven for either of both research questions.
Press releases
Dacomitinib in advanced lung cancer: large number of disadvantages outweighs survival advantage
Additional information
Federal Joint Committee (G-BA)
2019-10-17 A G-BA decision was published.
Project details
- Project no.
- A19-39
- Commission
- Commission awarded on 29.04.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.